BTG’s interventional medicine business was created through the acquisition of Biocompatibles, a medical device company with significant expertise in the field of drug-device combination products. Our primary products are drug-eluting and bland beads for the local and targeted treatment of liver cancer and the embolisation of blood vessels feeding tumours. In 2012, our interventional medicine sales force began direct sales of our bead products in the US. Varithena™ (polidocanol injectable foam) recieved US approval in November 2013 for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.
In addition, our interventional medicine business includes a number of development programmes including next generation drug-eluting beads.
BTG’s interventional medicine business development strategy is focussed on developing partnerships or acquiring businesses with late-stage or marketed products in the following areas:
- Products that target or enhance the delivery of loco-regional therapies for the treatment of cancer
- Products that can be sold through our interventional medicine sales channel
- Products that focus on disease areas treated by interventionalists with high unmet needs
For Business Development opportunities within Interventional Medicine, please send your enquiries to:
Arjun Krishnan, Director of Business Development
BTG International Ltd
We have a strong track record of partnering products successfully and a number of partnered programmes in late-stage development, which we believe may have significant commercial potential.